With the introduction of vaccines to prevent invasive meningococcal disease due serogroups ACWY, serogroup B now remains a major contributor to current disease burden, especially in Europe where it accounts for >50% of cases. Outer membrane vesicle (OMV) based vaccines have been used successfully to tackle clonal epidemics most recently in New Zealand and Normandy, however, these vaccines are strain specific and have limited utility on a global scale. Novartis and Pfizer vaccines are currently developing broader acting protein based vaccines, the former (4CmenB) is current undergoing registration in the EMA region.
This DiseaseINFOPACK product is a comprehensive research review detailing on a country-by-country basis all relevant aspects of meningococcus serogoup B epidemiology. As well as major Western markets the review also covers emerging market economies in the "Rest of World" (ROW) category. The review gives a global ranking of N. meningitidis (serogroup B) incidence. This product can be used in conjunction with the commercial analysis MarketVIEW : meningococcus serogoup B vaccines (CAT No: VAMV032), published January 2012.